Most Viewed Articles
| Articles | Fulltext downloads | PDF downloads | Total downloads |
|---|---|---|---|
Review ArticleAntibody-drug conjugate review in breast cancer: A targeted approachFull text |  PDF Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_30_2024 |
12,940 | 40,992 | 53,932 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text | PDF Volume 6 | Issue 1 | January-April 2021DOI: 10.25259/IJMIO_30_2020 |
48,474 | 3,965 | 52,439 |
Review ArticleGenetic diversity and variation in chronic myeloid leukemia patients of Indian origin- Implications for treatment response and prognosisFull text | PDF Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_11_2024 |
12,354 | 33,816 | 46,170 |
Short CommunicationDriver mutations in oncogenesisFull text | PDF Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_26_2020 |
40,621 | 5,256 | 45,877 |
Case ReportCase report – Muir–Torre syndrome – A skin-deep manifestation of underlying malignancyFull text | PDF Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_26_2024 |
12,231 | 32,908 | 45,139 |
Case ReportBreast carcinoma disguised as systemic sclerosis: A case report of unusual paraneoplastic syndromeFull text | PDF Volume 10 | Issue 1 | January-April 2025DOI: 10.25259/IJMIO_4_2024 |
11,131 | 22,469 | 33,600 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_12_2023 |
28,833 | 3,370 | 32,203 |
Review ArticleEmerging strategies in cancer immunotherapy: Expanding horizons and future perspectivesFull text | PDF Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_24_2024 |
13,980 | 18,150 | 32,130 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_20_2023 |
27,228 | 3,207 | 30,435 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_15_2023 |
27,152 | 3,081 | 30,233 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_16_2023 |
24,621 | 3,224 | 27,845 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_17_2023 |
23,144 | 2,430 | 25,574 |
Original ArticleSpectrum of lymphomas in IndiaFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_18_2023 |
19,763 | 3,214 | 22,977 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_2_2024 |
18,317 | 3,879 | 22,196 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_3_2024 |
18,481 | 3,559 | 22,040 |
NewsEditorial board tribute to Dr. Amit VermaFull text | PDF Volume 6 | Issue 3 | September-December 2021 |
16,819 | 4,258 | 21,077 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_1_2024 |
17,340 | 3,291 | 20,631 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_8_2022 |
14,337 | 6,246 | 20,583 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_5_2022 |
13,345 | 6,851 | 20,196 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text | PDF Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_22_2023 |
17,224 | 2,801 | 20,025 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_6_2023 |
15,869 | 3,152 | 19,021 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text | PDF Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_21_2019 |
13,951 | 4,889 | 18,840 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_1_2022 |
12,862 | 5,445 | 18,307 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_16_2021 |
14,795 | 3,181 | 17,976 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_29_2022 |
14,909 | 3,057 | 17,966 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_13_2021 |
14,662 | 2,976 | 17,638 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text | PDF Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_26_2021 |
11,673 | 5,665 | 17,338 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text | PDF Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_27_2022 |
15,510 | 1,781 | 17,291 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text | PDF Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_28_2022 |
15,167 | 2,122 | 17,289 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_2_2022 |
12,011 | 5,202 | 17,213 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text | PDF Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_15_2020 |
10,732 | 5,847 | 16,579 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text | PDF Volume 7 | Issue 3 | September-December 2022DOI: 10.25259/IJMIO_14_2022 |
11,259 | 5,303 | 16,562 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_3_2022 |
9,979 | 6,395 | 16,374 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text | PDF Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_22_2021 |
12,993 | 3,037 | 16,030 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text | PDF Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_36_2020 |
11,418 | 4,456 | 15,874 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text | PDF Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_2_2021 |
10,919 | 4,862 | 15,781 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text | PDF Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_11_2023 |
13,357 | 2,288 | 15,645 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text | PDF Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_28_2020 |
11,001 | 4,545 | 15,546 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_6_2021 |
12,220 | 3,307 | 15,527 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text | PDF Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_2_2019 |
9,431 | 6,082 | 15,513 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text | PDF Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_19_2019 |
9,971 | 5,325 | 15,296 |
Review ArticleEndocrine toxicity of cancer immunotherapyFull text | PDF Volume 9 | Issue 2 | May-August 2024DOI: 10.25259/IJMIO_19_2024 |
13,762 | 1,494 | 15,256 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_12_2021 |
11,732 | 3,503 | 15,235 |
Review ArticlePatient perspectives on living with chronic myeloid leukemia in India: Quality of life, psychosocial support, and stigmaFull text | PDF Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_17_2024 |
14,131 | 986 | 15,117 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text | PDF Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_18_2021 |
11,801 | 3,197 | 14,998 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text | PDF Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_11_2022 |
11,406 | 3,334 | 14,740 |
EditorialNanobytesFull text | PDF Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_7_2019 |
6,873 | 7,627 | 14,500 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_7_2021 |
10,894 | 3,577 | 14,471 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text | PDF Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_10_2021 |
11,044 | 3,344 | 14,388 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text | PDF Volume 6 | Issue 2 | October 2021DOI: 10.25259/IJMIO_05_2020_ER |
11,858 | 2,426 | 14,284 |
